We are live on ! Find out more
CA

Corriente Advisors Portfolio holdings

AUM $9.53M
1-Year Est. Return 805.26%
This Fund
S&P 500
This Quarter Est. Return
-15.89%
1 Year Est. Return
+805.26%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$92.6M
AUM Growth
-$93.5M
Cap. Flow
-$67.6M
Cap. Flow %
-72.92%
Top 10 Hldgs %
98.87%
Holding
23
New
6
Increased
2
Reduced
3
Closed
12

Top Buys

Rank Stock Value
1
APTO
Aptose Biosciences, Inc.
APTO
+$16.3M
2
CUE icon
Cue Biopharma
CUE
+$8.65M
3
PVLA
Palvella Therapeutics
PVLA
+$5.61M
4
EPZM
Epizyme, Inc
EPZM
+$4.94M
5
SDGR icon
Schrodinger
SDGR
+$2.27M

Top Sells

Rank Stock Value
1
SPCE icon
Virgin Galactic
SPCE
+$27.9M
2
QURE icon
uniQure
QURE
+$18.1M
3
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$17.8M
4
MAXR
Maxar Technologies Inc. Common Stock
MAXR
+$15.5M
5
I
INTELSAT S. A.
I
+$11.5M

Sector Composition

Rank Sector Weight
1 Healthcare 56.15%
2 Technology 19.47%
3 Consumer Discretionary 1.13%
4 Communication Services 0%
5 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RETA
1
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$27.4M 29.6%
190,000
-2,000
-1% -$386K
MAXR
2
DELISTED
Maxar Technologies Inc. Common Stock
MAXR
$18M 19.47%
1,689,100
-993,690
-37% -$15.5M
APTO
3
DELISTED
Aptose Biosciences, Inc.
APTO
$17.3M 18.71%
6,484
+5,477
+544% +$16.3M
CUE icon
4
Cue Biopharma
CUE
$131M
$11.6M 12.56%
27,333
+17,833
+188% +$8.65M
PVLA
5
Palvella Therapeutics
PVLA
$2.26B
$4.06M 4.39%
+22,274
New +$5.61M
EPZM
6
DELISTED
Epizyme, Inc
EPZM
$3.57M 3.85%
+230,000
New +$4.94M
SDGR icon
7
Schrodinger
SDGR
$1.14B
$2.59M 2.79%
+60,000
New +$2.27M
BLU
8
DELISTED
BELLUS Health Inc.
BLU
$1.48M 1.6%
148,666
-71,334
-32% -$636K
VIRX
9
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$1.25M 1.35%
+86,334
New +$1.87M
TSLA icon
10
Tesla
TSLA
$1.43T
$1.05M 1.13%
+30,000
New +$1.24M
ATXS
11
DELISTED
Astria Therapeutics
ATXS
– –
-102,847
Closed -$3.65M
DIS icon
12
Walt Disney
DIS
$170B
– –
-15,000
Closed -$2.17M
EQX icon
13
Equinox Gold
EQX
$6.8B
– –
-300,000
Closed -$2.31M
GFI icon
14
Gold Fields
GFI
$28.6B
– –
-250,000
Closed -$1.65M
QURE icon
15
uniQure
QURE
$2.77B
– –
-252,500
Closed -$18.1M
RCKT icon
16
Rocket Pharmaceuticals
RCKT
$376M
– –
-88,927
Closed -$2.02M
SPCE icon
17
Virgin Galactic
SPCE
$329M
– –
-120,586
Closed -$27.9M
EIGR
18
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
– –
-6,797
Closed -$3.04M
GBT
19
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-40,000
Closed -$3.18M
TPTX
20
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
– –
-285,000
Closed -$17.8M
I
21
DELISTED
INTELSAT S. A.
I
– –
-1,631,227
Closed -$11.5M
SPCE.WS
22
CALL
DELISTED
Virgin Galactic Holdings, Inc. Warrants, each whole warrant exercisable for one share of Common Stoc
SPCE.WS
– –
-252,983
Closed -$2.92M

Similar funds

SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
GIP
General Industrial Partners London, United Kingdom $2.57M AUM
LCMP
Linse Capital Management PR San Juan, Puerto Rico $2.31M AUM
SCM
SevenOneSeven Capital Management Lancaster, Pennsylvania $2.17M AUM 8.67% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return

Corriente Advisors's Q1 2020 Portfolio in Review

As of Q1 2020, Corriente Advisors held 23 positions worth $92.6M, down 50% from $186M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Corriente Advisors withdrew a net $67.6M in Q1 2020, closing 12 positions and reducing 3 holdings. Its most notable exit was Virgin Galactic, an estimated $27.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 56% of assets, up from 50% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, Corriente Advisors opened a new position in Palvella Therapeutics worth $4.06M.

  • Corriente Advisors's largest Q1 2020 buy was Palvella Therapeutics: 22,274 shares worth $4.06M.
  • Corriente Advisors added most to Aptose Biosciences, Inc. in Q1 2020, an estimated $16.3M increase.
  • Corriente Advisors's biggest Q1 2020 reduction was Maxar Technologies Inc. Common Stock, cutting an estimated $15.5M.
  • Corriente Advisors fully exited Virgin Galactic in Q1 2020, selling an estimated $27.9M.
  • Corriente Advisors's ten largest holdings make up 99% of its $92.6M portfolio in Q1 2020.
  • Corriente Advisors opened 6 new positions and closed 12 in Q1 2020.
  • Corriente Advisors's portfolio value fell 50% quarter-over-quarter to $92.6M.

Based on Corriente Advisors's 13F filing for Q1 2020, filed 18 May 2020.